618385-01-6 | Vorapaxar

Packsize	Purity	Availability	Price	Discounted Price
1mg	99+%	in stock	$28.00	$19.00
5mg	98%(HPLC)	in stock	$56.00	$39.00
10mg	98%(HPLC)	in stock	$83.00	$59.00
25mg	98%(HPLC)	in stock	$142.00	$99.00
50mg	98%(HPLC)	in stock	$223.00	$156.00
100mg	98%(HPLC)	in stock	$343.00	$240.00

Description

• Catalog Number: AG69131
• Chemical Name: Vorapaxar
• CAS Number: 618385-01-6
• Molecular Formula: C29H33FN2O4
• Molecular Weight: 492.5817
• MDL Number: MFCD16038876
• SMILES: CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C

Computed Properties

• Complexity: 821
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 7
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 5.3

Literature

• Vorapaxar in atherosclerotic disease management.

  The Annals of pharmacotherapy 20150501

• Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor.

  The American journal of cardiology 20150415

• Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.

  European journal of clinical pharmacology 20121101

• Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

  Lancet (London, England) 20121013

• Platelet protease-activated receptor antagonism in cardiovascular medicine.

  Coronary artery disease 20120901

• Developing PAR1 antagonists: minding the endothelial gap.

  Discovery medicine 20120601

• Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20120501

• Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.

  Expert review of cardiovascular therapy 20120301

• Promises of PAR-1 inhibition in acute coronary syndrome.

  Current cardiology reports 20120201

• Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

  The New England journal of medicine 20120105

• Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?

  Hamostaseologie 20120101

• Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.

  Advances in cardiology 20120101

• PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.

  Handbook of experimental pharmacology 20120101

• Vorapaxar: a novel protease-activated receptor-1 inhibitor.

  Expert opinion on investigational drugs 20111001

• Antiplatelet therapy: thrombin receptor antagonists.

  British journal of clinical pharmacology 20111001

• Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.

  American heart journal 20110301

• Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.

  Drug metabolism and disposition: the biological fate of chemicals 20110101

• Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.

  Expert opinion on investigational drugs 20101201

• Discovery of a vorapaxar analog with increased aqueous solubility.

  Bioorganic & medicinal chemistry letters 20101115

• Challenges and promises of developing thrombin receptor antagonists.

  Recent patents on cardiovascular drug discovery 20101101

• Emerging oral antiplatelet therapies for acute coronary syndromes.

  Hospital practice (1995) 20101101

• Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.

  Journal of cellular and molecular medicine 20101001

• Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.

  Drugs 20101001

• Mechanism of action and clinical development of platelet thrombin receptor antagonists.

  Expert review of cardiovascular therapy 20100801

• [Novel agents in antiplatelet therapy].

  Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 20100701

• Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.

  IDrugs : the investigational drugs journal 20100401

• Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.

  Journal of atherosclerosis and thrombosis 20100226

• Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.

  British journal of pharmacology 20100201

• Platelet thrombin receptor antagonism and atherothrombosis.

  European heart journal 20100101

• New antiplatelet agents: why they are needed.

  European journal of internal medicine 20091201

• Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

  Medical science monitor : international medical journal of experimental and clinical research 20091201

• Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets.

  British journal of pharmacology 20091101

• Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.

  Hamostaseologie 20091101

• SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.

  Current opinion in investigational drugs (London, England : 2000) 20090901

• SCH 530348: a novel oral thrombin receptor antagonist.

  Future cardiology 20090901

• New antiplatelet drugs: beyond aspirin and clopidogrel.

  International journal of clinical practice 20090501

• The ischaemia/bleeding balance in PCI.

  Lancet (London, England) 20090314

• Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.

  Lancet (London, England) 20090314

• Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.

  Recent patents on cardiovascular drug discovery 20090101

• Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• Advances in antiplatelet therapy for ACS and PCI.

  Journal of interventional cardiology 20081201

• Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.

  Journal of pharmacological sciences 20081201

• Pharmacology of emerging novel platelet inhibitors.

  American heart journal 20080801

• Clinical overview of promising nonthienopyridine antiplatelet agents.

  American heart journal 20080801

• Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

  Journal of medicinal chemistry 20080612